Details: pack, label wording, sources, registration
Neofleks Dextrose 10%, Solution
solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Controlled IV 10% dextrose for documented symptomatic or persistent hypoglycaemia, central-line glucose support, or dilution as a compatible drug/energy carrier; not volume resuscitation, routine maintenance fluid or complete parenteral nutrition
6.2/10
Situational / acceptable
Details →
vetman assessment
Neofleks Dextrose
×
10%, solution for infusion, human medicine
Assessed clinical scope Dog · Controlled IV 10% dextrose for documented symptomatic or persistent hypoglycaemia, central-line glucose support, or dilution as a compatible drug/energy carrier; not volume resuscitation, routine maintenance fluid or complete parenteral nutrition · Intravenous
Care setting Veterinary clinic or hospital with immediate point-of-care glucose measurement, central venous access or validated dilution for peripheral use, infusion control and serial glucose, electrolyte, osmolality and fluid-balance monitoring
vetman score
6.2/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-039076 · Verified on 16 Oct 2026
Off-label use
Clinically valuable for measured hypoglycaemia when rapid, titratable glucose is needed, but the exact 10% bag is a hypertonic hospital tool rather than a general-purpose fluid. Use a central line or validate peripheral dilution, monitor glucose and electrolytes closely, treat the cause, and avoid reflex continuation after the endpoint is reached.
Regulatory and scientific credibility 5.5/10
The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.
Clinical efficacy 7.0/10
IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.
Safety and tolerability 6.0/10
At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.
Clinical practicality 6.5/10
The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer 10% dextrose to a patient with clinically significant hyperglycaemia or known dextrose/excipient hypersensitivity. Confirm a reliable glucose result and the treatment endpoint; neurologic signs alone do not prove hypoglycaemia. Ten-percent dextrose is hypertonic and concentrations above 5% should preferably use a central venous line in dogs and cats. For peripheral delivery, prepare a validated lower final concentration aseptically, use a pump, inspect the catheter frequently and stop immediately for pain, swelling, erythema, phlebitis or extravasation. Do not administer 10% dextrose simultaneously with blood products through the same administration set because pseudoagglutination or haemolysis can occur. Use a separate compatible line and follow the blood component and exact fluid instructions. Measure glucose frequently during initiation and every rate change, then titrate to the lowest concentration and rate that controls clinical signs without marked hyperglycaemia. Excess delivery can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration and potentially fatal neurologic or fluid complications. Monitor potassium, phosphate, sodium, magnesium, osmolality, urine output and total fluid balance. Glucose-stimulated insulin can shift potassium and phosphate intracellularly; after dextrose metabolism the delivered water can contribute to dilutional hyponatraemia and overload, especially with renal, cardiac or pulmonary disease. In insulinoma or another hyperinsulinaemic state, large glucose boluses can provoke further insulin release and rebound hypoglycaemia. Treat symptomatic hypoglycaemia with the lowest effective dose, reassess rapidly, provide definitive disease management and consider alternative support when escalating dextrose fails. Do not use this electrolyte-free 10% solution for volume resuscitation, as a routine maintenance prescription or as complete parenteral nutrition. Correct hypovolaemia with an appropriate crystalloid, supply required electrolytes and nutrition separately, and include dextrose carrier volume in the total daily fluid plan. Before adding a medicine, confirm its prescribed diluent, final concentration, osmolarity, pH, stability and line compatibility from current instructions. Use only a clear intact single-dose container, maintain asepsis, never pool or share remnants and discard unused solution after the allowed handling interval. Assessment sources +
Close
Cat
Controlled IV 10% dextrose for documented symptomatic or persistent hypoglycaemia, central-line glucose support, or dilution as a compatible drug/energy carrier; not volume resuscitation, routine maintenance fluid or complete parenteral nutrition
6.2/10
Situational / acceptable
Details →
vetman assessment
Neofleks Dextrose
×
10%, solution for infusion, human medicine
Assessed clinical scope Cat · Controlled IV 10% dextrose for documented symptomatic or persistent hypoglycaemia, central-line glucose support, or dilution as a compatible drug/energy carrier; not volume resuscitation, routine maintenance fluid or complete parenteral nutrition · Intravenous
Care setting Veterinary clinic or hospital with immediate point-of-care glucose measurement, central venous access or validated dilution for peripheral use, infusion control and serial glucose, electrolyte, osmolality and fluid-balance monitoring
vetman score
6.2/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-039076 · Verified on 16 Oct 2026
Off-label use
Clinically valuable for measured hypoglycaemia when rapid, titratable glucose is needed, but the exact 10% bag is a hypertonic hospital tool rather than a general-purpose fluid. Use a central line or validate peripheral dilution, monitor glucose and electrolytes closely, treat the cause, and avoid reflex continuation after the endpoint is reached.
Regulatory and scientific credibility 5.5/10
The exact 10% human infusion has a sourced current Georgian registration with identifiable manufacturer, strength and IV route, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary administration is off-label; current foreign class labels and veterinary guidance support dextrose rather than any one of these exact products.
Clinical efficacy 7.0/10
IV dextrose is an established, rapidly effective intervention for clinically important hypoglycaemia in dogs and cats and is listed as an essential veterinary medicine. The exact 10% bag can supply a controlled infusion, but routine dog/cat guidance usually targets 1.25–5% after an initial bolus; benefit depends on diagnosing and treating the cause, and comparative exact-product outcome evidence is absent.
Safety and tolerability 6.0/10
At 100 mg/ml and about 505 mOsm/L, this is a hypertonic glucose solution. Excess dose or rate can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration, electrolyte shifts and fluid overload; peripheral infusion risks phlebitis and extravasation injury. Rapid glucose-driven insulin release can worsen hypokalaemia or hypophosphataemia and can produce rebound hypoglycaemia in hyperinsulinaemic disease.
Clinical practicality 6.5/10
The ready sterile bag permits a controlled central infusion and exact calculation at 0.1 g/ml, but concentrations above 5% are preferably central-line solutions in dogs and cats. Peripheral use generally requires aseptic dilution, compatibility and final-osmolality checks, an infusion pump, frequent bedside glucose measurement and a plan to taper or stop once oral/enteral control or normoglycaemia is sustained.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer 10% dextrose to a patient with clinically significant hyperglycaemia or known dextrose/excipient hypersensitivity. Confirm a reliable glucose result and the treatment endpoint; neurologic signs alone do not prove hypoglycaemia. Ten-percent dextrose is hypertonic and concentrations above 5% should preferably use a central venous line in dogs and cats. For peripheral delivery, prepare a validated lower final concentration aseptically, use a pump, inspect the catheter frequently and stop immediately for pain, swelling, erythema, phlebitis or extravasation. Do not administer 10% dextrose simultaneously with blood products through the same administration set because pseudoagglutination or haemolysis can occur. Use a separate compatible line and follow the blood component and exact fluid instructions. Measure glucose frequently during initiation and every rate change, then titrate to the lowest concentration and rate that controls clinical signs without marked hyperglycaemia. Excess delivery can cause hyperglycaemia, hyperosmolality, osmotic diuresis, dehydration and potentially fatal neurologic or fluid complications. Monitor potassium, phosphate, sodium, magnesium, osmolality, urine output and total fluid balance. Glucose-stimulated insulin can shift potassium and phosphate intracellularly; after dextrose metabolism the delivered water can contribute to dilutional hyponatraemia and overload, especially with renal, cardiac or pulmonary disease. In insulinoma or another hyperinsulinaemic state, large glucose boluses can provoke further insulin release and rebound hypoglycaemia. Treat symptomatic hypoglycaemia with the lowest effective dose, reassess rapidly, provide definitive disease management and consider alternative support when escalating dextrose fails. Do not use this electrolyte-free 10% solution for volume resuscitation, as a routine maintenance prescription or as complete parenteral nutrition. Correct hypovolaemia with an appropriate crystalloid, supply required electrolytes and nutrition separately, and include dextrose carrier volume in the total daily fluid plan. Before adding a medicine, confirm its prescribed diluent, final concentration, osmolarity, pH, stability and line compatibility from current instructions. Use only a clear intact single-dose container, maintain asepsis, never pool or share remnants and discard unused solution after the allowed handling interval. Assessment sources +
Close
Administration route
Intravenous
Registration
Georgia
Yes, human
In force until 14 Sep 2028
Human (Ministry of Health, RAMA)
In the register: ნეოფლექსი დექსტროზა 10%, საინფუზიო ხსნარი
№ რ-039076
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
